Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma

Rufini, Vittoria; Treglia, Giorgio; Castaldi, Paola; Perotti, Germano; Calcagni, Maria Lucia; Corsello, Salvatore Maria; Galli, G; Fanti, Stefano; Giordano, Alessandro

doi:10.1097/mnm.0b013e328345a340

Cited by 54 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the literature data, [ 18 F]DOPA PET and PET/CT seem to be accurate methods in both adrenal and extra-adrenal, sympathetic and parasympathetic, functioning and non-functioning, and metastatic and non-metastatic Pheo/PGL [16,[20][21][22][23][24][25][26][27][28][29][30][31]. In particular, [ 18 F]DOPA PET and PET/CT seem to be the most sensitive imaging methods for detecting head and neck PGLs, usually parasympatheticderived tumors, probably because of the high tracer avidity of these neoplasms and the favorable lesion-to-background ratio in the head and neck [21,30].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis

Rufini

Treglia

Montravers

et al. 2013

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis

Rufini

Treglia

Montravers

et al. 2013

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…The baseline differences among the patients in the included studies (Table 1) Nevertheless, according to the literature, 18 F-DOPA PET and PET/CT seem to be accurate methods in both adrenal [22,25,26,29] and extra-adrenal [23,24,30,31], sympathetic [22,[25][26][27] and parasympathetic [23,24,30,31], functioning [27] and non-functioning [23,26,31], metastatic and non-metastatic tumors [24,28,32]. Furthermore, 18 F-DOPA PET and PET/CT seem to be accurate methods in both sporadic and inherited PG [27,30], except in SDHB-related PG [28].…”

Section: Diagnostic Performancementioning

confidence: 97%

“…Finally, 11 studies, comprising a total sample size of 275 patients with suspected PG met all inclusion and exclusion criteria, and they were included in our meta-analysis [22][23][24][25][26][27][28][29][30][31][32] (Fig. 1).…”

Section: Literature Searchmentioning

confidence: 99%

Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis

Treglia

Cocciolillo

Waure

et al. 2012

Eur J Nucl Med Mol Imaging

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…Furthermore, MIBG may miss additional HNPs in hereditary syndromes. 18 F-FDOPA PET was found to be more sensitive than MIBG scintigraphy in the staging and restaging of paragangliomas (42,50,(54)(55)(56)(57)(58)(59). In some studies, 18 F-FDOPA PET significantly detected more lesions than CT/MRI.…”

Section: Extraadrenal Retroperitoneal Paragangliomasmentioning

confidence: 98%

Modern Nuclear Imaging for Paragangliomas: Beyond SPECT

et al. 2012

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the best nuclear imaging procedures to detect pheochromocytomas/paragangliomas according to the clinical situation (e.g., sporadic vs. hereditary; primary vs. metastatic; sympathetic vs. parasympathetic) and (2) the differences in the phenotypic information obtained by various PET tracers.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through February 2013.Paragangliomas are rare neuroendocrine tumors that may arise anywhere along the paraganglial system, with a high frequency of hereditary forms or multifocal disease. Most often, paragangliomas are benign and progress slowly, but metastases may occur in about 10% of patients. In this respect, nuclear imaging in combination with anatomic imaging may be required to fully delineate the extent of the disease. PET has been increasingly used in imaging paraganglioma, paralleled by great efforts toward the development of new tracers. Recent data indicate that the choice of PET tracers should be tailored to tumor localization and to the patient's genetic status. This article provides insight into the many PET radiotracers that are currently available and others that are still only under research and guides clinicians toward appropriate use in relation to genetic carrier status. In addition, this article provides nuclear medicine physicians with the background knowledge required for understanding relationships between imaging phenotypes and molecular genetics.

show abstract

Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma

Cited by 54 publications

References 24 publications

Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis

Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis

Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis

Modern Nuclear Imaging for Paragangliomas: Beyond SPECT

Contact Info

Product

Resources

About